Cargando…
Natural killer cells as a therapeutic tool for infectious diseases – current status and future perspectives
Natural Killer (NK) cells are involved in the host immune response against infections due to viral, bacterial and fungal pathogens, all of which are a significant cause of morbidity and mortality in immunocompromised patients. Since the recovery of the immune system has a major impact on the outcome...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945539/ https://www.ncbi.nlm.nih.gov/pubmed/29755697 http://dx.doi.org/10.18632/oncotarget.25058 |
_version_ | 1783322010007371776 |
---|---|
author | Schmidt, Stanislaw Tramsen, Lars Rais, Bushra Ullrich, Evelyn Lehrnbecher, Thomas |
author_facet | Schmidt, Stanislaw Tramsen, Lars Rais, Bushra Ullrich, Evelyn Lehrnbecher, Thomas |
author_sort | Schmidt, Stanislaw |
collection | PubMed |
description | Natural Killer (NK) cells are involved in the host immune response against infections due to viral, bacterial and fungal pathogens, all of which are a significant cause of morbidity and mortality in immunocompromised patients. Since the recovery of the immune system has a major impact on the outcome of an infectious complication, there is major interest in strengthening the host response in immunocompromised patients, either by using cytokines or growth factors or by adoptive cellular therapies transfusing immune cells such as granulocytes or pathogen-specific T-cells. To date, relatively little is known about the potential of adoptively transferring NK cells in immunocompromised patients with infectious complications, although the anti-cancer property of NK cells is already being investigated in the clinical setting. This review will focus on the antimicrobial properties of NK cells and the current standing and future perspectives of generating and using NK cells as immunotherapy in patients with infectious complications, an approach which is promising and might have an important clinical impact in the future. |
format | Online Article Text |
id | pubmed-5945539 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-59455392018-05-13 Natural killer cells as a therapeutic tool for infectious diseases – current status and future perspectives Schmidt, Stanislaw Tramsen, Lars Rais, Bushra Ullrich, Evelyn Lehrnbecher, Thomas Oncotarget Review Natural Killer (NK) cells are involved in the host immune response against infections due to viral, bacterial and fungal pathogens, all of which are a significant cause of morbidity and mortality in immunocompromised patients. Since the recovery of the immune system has a major impact on the outcome of an infectious complication, there is major interest in strengthening the host response in immunocompromised patients, either by using cytokines or growth factors or by adoptive cellular therapies transfusing immune cells such as granulocytes or pathogen-specific T-cells. To date, relatively little is known about the potential of adoptively transferring NK cells in immunocompromised patients with infectious complications, although the anti-cancer property of NK cells is already being investigated in the clinical setting. This review will focus on the antimicrobial properties of NK cells and the current standing and future perspectives of generating and using NK cells as immunotherapy in patients with infectious complications, an approach which is promising and might have an important clinical impact in the future. Impact Journals LLC 2018-04-17 /pmc/articles/PMC5945539/ /pubmed/29755697 http://dx.doi.org/10.18632/oncotarget.25058 Text en Copyright: © 2018 Schmidt et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Schmidt, Stanislaw Tramsen, Lars Rais, Bushra Ullrich, Evelyn Lehrnbecher, Thomas Natural killer cells as a therapeutic tool for infectious diseases – current status and future perspectives |
title | Natural killer cells as a therapeutic tool for infectious diseases – current status and future perspectives |
title_full | Natural killer cells as a therapeutic tool for infectious diseases – current status and future perspectives |
title_fullStr | Natural killer cells as a therapeutic tool for infectious diseases – current status and future perspectives |
title_full_unstemmed | Natural killer cells as a therapeutic tool for infectious diseases – current status and future perspectives |
title_short | Natural killer cells as a therapeutic tool for infectious diseases – current status and future perspectives |
title_sort | natural killer cells as a therapeutic tool for infectious diseases – current status and future perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945539/ https://www.ncbi.nlm.nih.gov/pubmed/29755697 http://dx.doi.org/10.18632/oncotarget.25058 |
work_keys_str_mv | AT schmidtstanislaw naturalkillercellsasatherapeutictoolforinfectiousdiseasescurrentstatusandfutureperspectives AT tramsenlars naturalkillercellsasatherapeutictoolforinfectiousdiseasescurrentstatusandfutureperspectives AT raisbushra naturalkillercellsasatherapeutictoolforinfectiousdiseasescurrentstatusandfutureperspectives AT ullrichevelyn naturalkillercellsasatherapeutictoolforinfectiousdiseasescurrentstatusandfutureperspectives AT lehrnbecherthomas naturalkillercellsasatherapeutictoolforinfectiousdiseasescurrentstatusandfutureperspectives |